Trials / Temporarily Not Available
Temporarily Not AvailableNCT07535359
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
Medical Access Program for Ifinatamab Deruxtecan (I-DXd, DS-7300a)
- Status
- Temporarily Not Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to I-DXd for eligible patients with extensive-stage small cell lung cancer (ES-SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen), and for eligible patients who have no suitable treatment options and are not able to enter a clinical study.
Detailed description
A patient enrolled in this MAP can continue treatment until any of the following occurs (whichever comes first): * Disease progression. * Unacceptable toxicity. * The benefit-risk no longer favors the individual. * I-DXd becomes commercially available in the US, and reimbursement is approved for the treatment of ES-SCLC. * The patient chooses to discontinue treatment. * Withdrawal of consent. * Pregnancy. * Physician discretion. * Death.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ifinatamab Deruxtecan | 12 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle) |
Timeline
- First posted
- 2026-04-17
- Last updated
- 2026-04-17
Source: ClinicalTrials.gov record NCT07535359. Inclusion in this directory is not an endorsement.